

August 01, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Press Release

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the Press Release of the Company for the First Quarter ended June 30, 2025.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

Rudalf Corriea
Company Secretary and Compliance Officer

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

Corporate Office:

4th Floor, OIA House, 470, Cardinal Gracious Road
Andheri (E), Mumbai 400 099, Maharashtra, India

Registered Office:

Plot No 170-172, Chandramouli Industrial Estate
Mohol Bazarpeth, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com



PRESS RELEASE

For Immediate dissemination



Alivus Life Sciences reports revenue of Rs. 6,018 Mn for Q1FY26,

Gross Margins of 55.1%, up 400 bps YoY and EBITDA Margins at 30.1%, up 210 bps YoY

Mumbai, August 1, 2025: Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited), a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced its financial results for the quarter ended June 30, 2025.

Revenue from operations for Q1FY26 reached Rs. 6,018 Mn, a growth of 2.2% YoY.

For Q1FY26, EBITDA was at Rs. 1,813 Mn, a growth of 9.9% YoY. EBITDA margins were at 30.1%, up 210 bps YoY.

PAT for the quarter stood at Rs. 1,215 Mn and PAT margins were at 20.2%.

During Q1FY26, the company generated a strong free cash flow of Rs. 1,000 Mn leading to Cash and Cash Equivalents (including short term investments) of Rs. 6,604 Mn as of June 30, 2025.

Commenting on the company's performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, *"Our performance this quarter was primarily driven by strong growth in the Non-GPL business, which expanded by 14.5% YoY. Key regions including India (Ex-GPL), Europe, ROW, LATAM, and Japan were major contributors to this growth. We remain confident of achieving high single-digit revenue growth in FY26, with stronger momentum expected in the second half. Margins are projected to remain healthy in the 28–30% range.*

Our ongoing investments in capacity building and pipeline enrichment form the foundation of our future growth, and we believe these efforts, supported by an increasingly favourable market environment, will help unlock further value."

Tushar Mistry, CFO, Alivus Life Sciences Limited said, *"Q1FY26 witnessed robust revenues of Rs. 602 crores, while consistently maintaining our gross margin at ~55% and EBITDA margin around ~30%, well within our guided range.*

This financial discipline, coupled with a healthy free cash flow of Rs. 100 crores during the quarter, strengthens our debt-free balance sheet and positions us well to achieve the high single-digit growth we anticipate for the full year."

Additional Highlights:

- DMF / CEP filings continue across major markets, taking the total cumulative filings to 569 as on June 30, 2025
- In Q1FY26, five synthetic small molecules were added to the development grid
- The HP API portfolio has 26 APIs in the active grid with nine products validated, three products in advanced stages of development and 14 products under lab development stage

Capex Update:

- Solapur – Phase 1 construction work is in progress for 200 KL capacity

PRESS RELEASE

For Immediate dissemination



About Alivus Life Sciences Ltd (ALIVUS)

Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited) (BSE: 543322, NSE: ALIVUS), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 170 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

The company's four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). Alivus Life Sciences is listed on BSE and NSE.

Learn more about Alivus Life Sciences Limited on <https://www.alivus.com>

For any further queries please contact:

Soumi Rao | General Manager – Corporate Communications

Email: Soumi.Rao@glenmarklifesciences.com

Mobile: 98701 96931

Ernst & Young LLP – Investor Relations

Diwakar Pingle

Email: Diwakar.Pingle@in.ey.com

Runjhun Jain

Email: Runjhun.Jain1@in.ey.com

Sneha Salian

Email: Sneha2.Salian@in.ey.com